Hearing Loss

A low-cost otoacoustic emission probe and smartphone app performed as well as commercially available devices for hearing loss screening in infants aged younger than 6 months, according to a study published in Pediatrics.

A novel drug delivery construct may protect individuals against cisplatin-induced ototoxicity and associated hearing loss.

Adults receiving teprotumumab for the treatment of thyroid eye disease experience a similar number of hearing-related adverse events as those not treated with teprotumumab, according to new data.

PHILADELPHIA — Tackling 14 risk factors for dementia beginning in childhood could prevent or delay nearly half of cases, according to a report from the Lancet Commission presented at the Alzheimer's Association International Conference.

A longitudinal cohort study has yielded new insights into risks for and long-term effects of cisplatin-related hearing loss.

Addressing disparities in standard of care in disease monitoring and perception of disease progression could improve treatment for adults with Fabry disease, according to published data.

A recent analysis found that factors like age, BMI and diabetes status did not significantly affect improvements in sexual function or quality of life for men receiving testosterone replacement therapy.

Hearing loss occurred more frequently among adults who received teprotumumab for the treatment of thyroid eye disease if they had impaired hearing at the start of therapy, according to a research letter published in Thyroid.

Hearing loss was associated with an increased risk for mortality, but the risk was reduced among those who regularly used hearing aids, according to a recent study.

Hearing loss was linked to a higher risk for dementia, and this risk was greater among people who did not use a hearing aid than those who did, a recent study in JAMA Otolaryngology – Head and Neck Surgery found.